Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)

Update Il y a 4 ans
Reference: NCT01025596

Woman and Man

Extract

This study will evaluate the safety of a new experimental drug, IL-7, in people with HCV infection resistant after 12 weeks of bi-therapy.


Inclusion criteria

  • Hepatitis C

Links